Arash Nayeri is a Cardiology physician affiliated with Cedars-Sinai Smidt Heart Institute. OpenAlex indexes 40 publications with 310 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
757 Westwood Plz Ste 7501
Los Angeles, CA 900957417
Telephone
310-383-5085Provider last certified this registry record 2 Nov 2022.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year202578 payments$83,498openpaymentsdata.cms.gov ↗
- HEARTFLOW, INC.Program year202537 payments$41,032openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
72%Statin20.4%Rosuvastatin Calcium74%Atorvastatin Calcium22%Pravastatin Sodium3%Simvastatin2%Part D<11 patientsBeta blocker8.6%Metoprolol Succinate60%Carvedilol28%Propranolol Hcl7%Atenolol6%Part D<11 patients+ 13 more classes in this area
Blood & clotting
11.8%Factor Xa inhibitor9.1%Eliquis100%Part D≥49 patientsP2Y12 inhibitor2.7%Clopidogrel85%Brilinta15%Part D<11 patientsMetabolism & gastrointestinal
10.1%SGLT2 inhibitor3.7%Farxiga65%Jardiance24%Inpefa11%Part D<11 patientsGLP-1 receptor agonist3.5%Ozempic58%Mounjaro42%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
Journal of Cardiovascular Development and Disease
2025 - ESTIMATION OF ECHOCARDIOGRAPHIC PARAMETERS OF SYSTOLIC FUNCTION FROM ANALYSIS OF PHOTOPLETHYSMOGRAPHY BASED ARTERIAL PULSE WAVE USING AUTOMATED FEATURE SELECTION
Journal of the American College of Cardiology
2023 - Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
Journal of the American College of Cardiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Aakriti Gupta, MD, BS
Cedars-Sinai Smidt Heart Institute
Joshua Goldhaber, MD
Cedars-Sinai Smidt Heart Institute
Janet Wei, MD
Cedars-Sinai Smidt Heart Institute
Eugenio Cingolani, MD
Cedars-Sinai Smidt Heart Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”